CN109316470A - 一种含有布比卡因的药物组合物及其制备方法和用途 - Google Patents
一种含有布比卡因的药物组合物及其制备方法和用途 Download PDFInfo
- Publication number
- CN109316470A CN109316470A CN201811308025.2A CN201811308025A CN109316470A CN 109316470 A CN109316470 A CN 109316470A CN 201811308025 A CN201811308025 A CN 201811308025A CN 109316470 A CN109316470 A CN 109316470A
- Authority
- CN
- China
- Prior art keywords
- bupivacaine
- pharmaceutical composition
- composition according
- nano
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960003150 bupivacaine Drugs 0.000 title claims abstract description 122
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 title claims abstract description 106
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 31
- 238000002360 preparation method Methods 0.000 title claims abstract description 23
- 150000003839 salts Chemical class 0.000 claims abstract description 16
- SIEYLFHKZGLBNX-UHFFFAOYSA-N bupivacaine hydrochloride (anhydrous) Chemical compound [Cl-].CCCC[NH+]1CCCCC1C(=O)NC1=C(C)C=CC=C1C SIEYLFHKZGLBNX-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000000463 material Substances 0.000 claims abstract description 13
- 239000012876 carrier material Substances 0.000 claims abstract description 12
- 238000010041 electrostatic spinning Methods 0.000 claims abstract description 10
- 239000000470 constituent Substances 0.000 claims abstract description 6
- 239000003937 drug carrier Substances 0.000 claims abstract description 4
- 229920002521 macromolecule Polymers 0.000 claims abstract description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 18
- 239000000243 solution Substances 0.000 claims description 16
- 208000002193 Pain Diseases 0.000 claims description 14
- 238000009987 spinning Methods 0.000 claims description 14
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 12
- -1 poly- hexanol ester Chemical class 0.000 claims description 12
- 239000000843 powder Substances 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- 229920001610 polycaprolactone Polymers 0.000 claims description 11
- 230000003444 anaesthetic effect Effects 0.000 claims description 10
- 239000012153 distilled water Substances 0.000 claims description 10
- 229920000771 poly (alkylcyanoacrylate) Polymers 0.000 claims description 10
- 238000005406 washing Methods 0.000 claims description 10
- HLHSUNWAPXINQU-GQCTYLIASA-N (E)-3-(3,4-dihydroxyphenyl)-N-prop-2-ynylprop-2-enamide Chemical compound OC=1C=C(C=CC=1O)/C=C/C(=O)NCC#C HLHSUNWAPXINQU-GQCTYLIASA-N 0.000 claims description 9
- 208000035823 Non-specific autoimmune cerebellar ataxia without characteristic antibodies Diseases 0.000 claims description 8
- 230000005684 electric field Effects 0.000 claims description 8
- 239000011259 mixed solution Substances 0.000 claims description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 6
- 238000013019 agitation Methods 0.000 claims description 6
- 239000003513 alkali Substances 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 230000002980 postoperative effect Effects 0.000 claims description 5
- 230000001376 precipitating effect Effects 0.000 claims description 5
- 230000036592 analgesia Effects 0.000 claims description 4
- 229960001050 bupivacaine hydrochloride Drugs 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 239000003589 local anesthetic agent Substances 0.000 claims description 4
- 239000012528 membrane Substances 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- JCQBWMAWTUBARI-UHFFFAOYSA-N tert-butyl 3-ethenylpiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC(C=C)C1 JCQBWMAWTUBARI-UHFFFAOYSA-N 0.000 claims description 4
- JRHWHSJDIILJAT-UHFFFAOYSA-N 2-hydroxypentanoic acid Chemical compound CCCC(O)C(O)=O JRHWHSJDIILJAT-UHFFFAOYSA-N 0.000 claims description 3
- SJZRECIVHVDYJC-UHFFFAOYSA-N 4-hydroxybutyric acid Chemical compound OCCCC(O)=O SJZRECIVHVDYJC-UHFFFAOYSA-N 0.000 claims description 3
- 239000004744 fabric Substances 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N n-hexyl alcohol Natural products CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 238000003860 storage Methods 0.000 claims description 3
- 208000000094 Chronic Pain Diseases 0.000 claims description 2
- 229920002730 Poly(butyl cyanoacrylate) Polymers 0.000 claims description 2
- LCAWNFIFMLXZPQ-UHFFFAOYSA-N ST055982 Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC=C(O)C=C2O1 LCAWNFIFMLXZPQ-UHFFFAOYSA-N 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 208000005298 acute pain Diseases 0.000 claims description 2
- 238000001838 alkalimetric titration Methods 0.000 claims description 2
- 239000005030 aluminium foil Substances 0.000 claims description 2
- DZOKWSREAZGFFC-UHFFFAOYSA-N dehydrofukinone Natural products O=C1C(=C(C)C)CC2(C)C(C)CCCC2=C1 DZOKWSREAZGFFC-UHFFFAOYSA-N 0.000 claims description 2
- 238000003825 pressing Methods 0.000 claims description 2
- 239000003960 organic solvent Substances 0.000 claims 3
- 230000005611 electricity Effects 0.000 claims 1
- 238000002156 mixing Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 33
- 229940079593 drug Drugs 0.000 abstract description 29
- 230000000202 analgesic effect Effects 0.000 abstract description 16
- 230000000694 effects Effects 0.000 abstract description 11
- 230000009471 action Effects 0.000 abstract description 5
- 238000005516 engineering process Methods 0.000 abstract description 5
- 238000013268 sustained release Methods 0.000 abstract description 5
- 239000012730 sustained-release form Substances 0.000 abstract description 5
- 230000002209 hydrophobic effect Effects 0.000 abstract description 4
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 208000019622 heart disease Diseases 0.000 abstract description 3
- 241000700159 Rattus Species 0.000 description 13
- 238000012360 testing method Methods 0.000 description 12
- 238000002347 injection Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 230000036407 pain Effects 0.000 description 10
- 239000004632 polycaprolactone Substances 0.000 description 8
- 206010002091 Anaesthesia Diseases 0.000 description 7
- 230000037005 anaesthesia Effects 0.000 description 7
- 239000002105 nanoparticle Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 206010001497 Agitation Diseases 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 210000005036 nerve Anatomy 0.000 description 5
- 208000004550 Postoperative Pain Diseases 0.000 description 4
- 206010052428 Wound Diseases 0.000 description 4
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 229960004194 lidocaine Drugs 0.000 description 4
- 239000013558 reference substance Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- BYEAHWXPCBROCE-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-ol Chemical compound FC(F)(F)C(O)C(F)(F)F BYEAHWXPCBROCE-UHFFFAOYSA-N 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000006838 adverse reaction Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000007731 hot pressing Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 229960005015 local anesthetics Drugs 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 239000004626 polylactic acid Substances 0.000 description 3
- 229960004919 procaine Drugs 0.000 description 3
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 210000001951 dura mater Anatomy 0.000 description 2
- 229940042577 exparel Drugs 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 230000005923 long-lasting effect Effects 0.000 description 2
- 239000002075 main ingredient Substances 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000005250 spinal neuron Anatomy 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 239000008896 Opium Substances 0.000 description 1
- 208000034530 PLAA-associated neurodevelopmental disease Diseases 0.000 description 1
- 208000000114 Pain Threshold Diseases 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 108010052164 Sodium Channels Proteins 0.000 description 1
- 102000018674 Sodium Channels Human genes 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 206010047281 Ventricular arrhythmia Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000746 body region Anatomy 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 208000012549 congenital acardia Diseases 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000007831 electrophysiology Effects 0.000 description 1
- 238000002001 electrophysiology Methods 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000012395 formulation development Methods 0.000 description 1
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000000917 hyperalgesic effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 230000036640 muscle relaxation Effects 0.000 description 1
- 239000006070 nanosuspension Substances 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 230000007830 nerve conduction Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 230000003961 neuronal insult Effects 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 230000002887 neurotoxic effect Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 229960001027 opium Drugs 0.000 description 1
- 230000037040 pain threshold Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 238000012805 post-processing Methods 0.000 description 1
- 230000036316 preload Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 230000037152 sensory function Effects 0.000 description 1
- 230000020341 sensory perception of pain Effects 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 210000003594 spinal ganglia Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (17)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811308025.2A CN109316470A (zh) | 2018-11-05 | 2018-11-05 | 一种含有布比卡因的药物组合物及其制备方法和用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811308025.2A CN109316470A (zh) | 2018-11-05 | 2018-11-05 | 一种含有布比卡因的药物组合物及其制备方法和用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN109316470A true CN109316470A (zh) | 2019-02-12 |
Family
ID=65261060
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811308025.2A Pending CN109316470A (zh) | 2018-11-05 | 2018-11-05 | 一种含有布比卡因的药物组合物及其制备方法和用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109316470A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114177133A (zh) * | 2021-12-17 | 2022-03-15 | 中国医学科学院北京协和医院 | 一种药物缓释载体、缓释药物组合物及其应用 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1583182A (zh) * | 2004-06-08 | 2005-02-23 | 东华大学 | 用于人体局部麻醉的局部麻醉纤维产品及制备方法 |
JP2006036638A (ja) * | 2004-07-22 | 2006-02-09 | Terumo Corp | 微細炭素繊維への親水性物質付着方法 |
US20090264472A1 (en) * | 2008-04-18 | 2009-10-22 | Warsaw Orthopedic, Inc. | Methods and compositions for treating post-operative pain comprising a local anesthetic |
US20100166854A1 (en) * | 2006-10-30 | 2010-07-01 | Rutgers, The State University Of New Jersey | Electrospun matrices for delivery of hydrophilic and lipophilic compounds |
CN107157960A (zh) * | 2017-04-19 | 2017-09-15 | 苏州大学 | 一种载药纳米纤维膜的制备方法 |
CN107185025A (zh) * | 2017-05-26 | 2017-09-22 | 吉林大学 | 一种中药纳米纺丝复合纤维膜敷料、制备方法及其应用 |
CN107397721A (zh) * | 2016-05-18 | 2017-11-28 | 中国医学科学院基础医学研究所 | 含有布比卡因的药物组合物及其制备方法和用途 |
-
2018
- 2018-11-05 CN CN201811308025.2A patent/CN109316470A/zh active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1583182A (zh) * | 2004-06-08 | 2005-02-23 | 东华大学 | 用于人体局部麻醉的局部麻醉纤维产品及制备方法 |
JP2006036638A (ja) * | 2004-07-22 | 2006-02-09 | Terumo Corp | 微細炭素繊維への親水性物質付着方法 |
US20100166854A1 (en) * | 2006-10-30 | 2010-07-01 | Rutgers, The State University Of New Jersey | Electrospun matrices for delivery of hydrophilic and lipophilic compounds |
US20090264472A1 (en) * | 2008-04-18 | 2009-10-22 | Warsaw Orthopedic, Inc. | Methods and compositions for treating post-operative pain comprising a local anesthetic |
CN107397721A (zh) * | 2016-05-18 | 2017-11-28 | 中国医学科学院基础医学研究所 | 含有布比卡因的药物组合物及其制备方法和用途 |
CN107157960A (zh) * | 2017-04-19 | 2017-09-15 | 苏州大学 | 一种载药纳米纤维膜的制备方法 |
CN107185025A (zh) * | 2017-05-26 | 2017-09-22 | 吉林大学 | 一种中药纳米纺丝复合纤维膜敷料、制备方法及其应用 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114177133A (zh) * | 2021-12-17 | 2022-03-15 | 中国医学科学院北京协和医院 | 一种药物缓释载体、缓释药物组合物及其应用 |
CN114177133B (zh) * | 2021-12-17 | 2023-02-21 | 中国医学科学院北京协和医院 | 一种药物缓释载体、缓释药物组合物及其应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2016159240A1 (ja) | エレクトロスピニングを用いた、薬剤を含有する生分解性繊維素材の製造方法 | |
DE3650776T2 (de) | Polysaccharideester und ihre Salze | |
CN106344521B (zh) | 一种高载药量可生物降解布比卡因微球的制备及其应用 | |
JP5571069B2 (ja) | 皮膚病変を治療するためのオピオイド組成物 | |
JP2016069378A (ja) | 手術後の慢性の痛みのための薬物充填マイクロスフェア | |
AU2005287175A1 (en) | Sustained local anesthetic composition containing preferably a sugar ester such as SAIB | |
WO2006048829A2 (en) | Preparation of chitin and derivatives thereof for cosmetic and therapeutic use | |
CN108379269A (zh) | 一种用于术后镇痛的缓释制剂及其制备方法 | |
KR20170056573A (ko) | 치료제의 고도로 국소화된 방출을 위한 주입가능한 미립자 | |
CN110123779A (zh) | 一种用于关节腔内注射的微球及其制备方法 | |
He et al. | Electrospun PLGA nanomembrane: A novel formulation of extended-release bupivacaine delivery reducing postoperative pain | |
CN110025599A (zh) | 一种布洛芬透皮缓释制剂的制备方法 | |
Sun et al. | Laden nanofiber capsules for local malignancy chemotherapy | |
Chen et al. | Injectable electrospun fiber-hydrogel composite sequentially releasing clonidine and ropivacaine for prolonged and walking regional analgesia | |
CN108912349A (zh) | 聚乳酸微球及其制备方法与在药物缓释中的应用 | |
KR20160145476A (ko) | 센텔라아시아티카를 함유한 용해성 마이크로니들 패치 | |
CN1973840A (zh) | 一种用于戒毒的长效缓释制剂及其制备方法和用途 | |
Guo et al. | Achieving long-acting local analgesia using an intelligent hydrogel encapsulated with drug and pH regulator | |
CN109316470A (zh) | 一种含有布比卡因的药物组合物及其制备方法和用途 | |
CN102614106B (zh) | 一种药物控释纳米纤维及其制备方法 | |
CN110101660B (zh) | 一种包含有地佐辛与利卡多因的复方药物缓释制剂及其制备方法 | |
CN107397721B (zh) | 含有布比卡因的药物组合物及其制备方法和用途 | |
CN105997889B (zh) | 一种皮下注射用氨磷汀缓释微球及其制备方法 | |
CN116211799B (zh) | 一种局麻药复合物混悬剂 | |
WO2022193975A1 (zh) | 供注射用罗哌卡因长效溶液制剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20230704 Address after: No. 1200, Xinghai North Road, Taoyuan Street, Ninghai County, Ningbo City, Zhejiang Province Applicant after: Ningbo qizhinianhua Medical Technology Co.,Ltd. Address before: No. 5 Dongdan Santiao, Dongcheng District, Beijing, 100007 Applicant before: INSTITUTE OF BASIC MEDICAL SCIENCES, CHINESE ACADEMY OF MEDICAL SCIENCES |
|
TA01 | Transfer of patent application right | ||
CB02 | Change of applicant information |
Country or region after: China Address after: No. 1200, Xinghai North Road, Taoyuan Street, Ninghai County, Ningbo City, Zhejiang Province Applicant after: Korui Medical Technology (Ningbo) Co.,Ltd. Address before: No. 1200, Xinghai North Road, Taoyuan Street, Ninghai County, Ningbo City, Zhejiang Province Applicant before: Ningbo qizhinianhua Medical Technology Co.,Ltd. Country or region before: China |
|
CB02 | Change of applicant information | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190212 |